# US 2019/0375737 A1 · Quinoline alkenes as cytoprotective agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375737 A1
- Document ID: US20190375737A1
- Status: Published application
- Kind: A1
- Application number: 16/436,843
- Filed: 2019-06-10
- Published: 2019-12-12
- Earliest claimed: 2015-11-28
- Inventors: Russell Dahl
- Web page: https://patentgrep.com/patent/US20190375737A1

## CPC

- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07D 215/06: having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
- C07D 215/14: Radicals substituted by oxygen atoms
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are compounds of Formula I, pharmaceutical compositions thereof, and methods of their use for treating, preventing, or ameliorating one or more symptoms of a neurological disease, neurodegenerative disorder, or diabetes.

## Claims

### Claim 1

A compound of Formula I:
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof;
wherein:
R2 is (a) hydrogen or (b) methyl;
R3, R4, R5, R6, and R7 are each independently (a) hydrogen, cyano, or halo; (b) C1-6 alkyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c,
—OR1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d;
each R1a, R1b, R1c, and R1d is independently (i) hydrogen; (ii) C1-6 alkyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (iii) R1b and R1c together with the N atom to which they are attached form heterocyclyl; and
R1 is aryl or heteroaryl with the proviso that R1 is not Ph, 4-Me-Ph, 4-OMe-Ph, 4-Br-Ph, 4-OH-Ph, 4-COOMe-Ph, 4-CN-Ph, 4-Ph-Ph, 2-Naphthyl, or 4-NO2-Ph.

### Claim 2 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl.

### Claim 3 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R3, R4, R5, R6, and R7 are hydrogen.

### Claim 4 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is methyl and R3, R4, R5, R6, and R7 are hydrogen.

### Claim 5 (depends on 1)

The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is mono or disubstituted phenyl or mono or disubstituted 2-thienyl with the proviso that R1 is not Ph, 4-Me-Ph, 4-OMe-Ph, 4-Br-Ph, 4-OH-Ph, 4-COOMe-Ph, 4-CN-Ph, 4-Ph-Ph, 2-Naphthyl, or 4-NO2-Ph.

### Claim 6 (depends on 1)

The compound according to claim 1 selected from the group consisting of:

### Claim 7

A method for treating a neurological or neurodegenerative disorder in a subject comprising administering to the subject an effective amount of a compound of Formula I
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof, or a pharmaceutically acceptable salt, solvate, or hydrate thereof;
wherein:
R2 is (a) hydrogen or (b) methyl;
R3, R4, R5, R6, and R7 are each independently (a) hydrogen, cyano, or halo; (b) C1-6 alkyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c,
—OR1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d;
each R1a, R1b, R1c, and R1d is independently (i) hydrogen; (ii) C1-6 alkyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (iii) R1b and R1c together with the N atom to which they are attached form heterocyclyl; and
R1 is aryl or heteroaryl with the proviso that R1 is not Ph, 4-Me-Ph, 4-OMe-Ph, 4-Br-Ph, 4-OH-Ph, 4-COOMe-Ph, 4-CN-Ph, 4-Ph-Ph, 2-Naphthyl, or 4-NO2-Ph.

### Claim 8

A method for treating, preventing, or ameliorating one or more symptoms of diabetes in a subject in need thereof comprising administering to the subject an effective amount of the compound Formula I
or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof;
wherein:
R2 is (a) hydrogen or (b) methyl;
R3, R4, R5, R6, and R7 are each independently (a) hydrogen, cyano, or halo; (b) C1-6 alkyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (c) —C(O)R1a, —C(O)OR1a, —C(O)NR1bR1c, —C(NR1a)NR1bR1c,
—OR1a, —OS(O)NR1bR1c, —OS(O)2NR1bR1c, —NR1bR1c, —NR1aC(O)R1d, —NR1aC(O)OR1d, —NR1aC(O)NR1bR1c, —NR1aS(O)R1d, —NR1aS(O)2R1d;
each R1a, R1b, R1c, and R1d is independently (i) hydrogen; (ii) C1-6 alkyl, C3-10 cycloalkyl, C6-14 aryl, C7-15 aralkyl, heteroaryl, or heterocyclyl; or (iii) R1b and R1c together with the N atom to which they are attached form heterocyclyl; and
R1 is aryl or heteroaryl with the proviso that R1 is not Ph, 4-Me-Ph, 4-OMe-Ph, 4-Br-Ph, 4-OH-Ph, 4-COOMe-Ph, 4-CN-Ph, 4-Ph-Ph, 2-Naphthyl, or 4-NO2-Ph

### Claim 9 (depends on 7)

The method of claim 7 wherein the neurological or neurodegenerative disorder is Alzheimer's disease.

### Claim 10 (depends on 7)

The method of claim 7 wherein the neurological or neurodegenerative disorder is Parkinson's disease.

### Claim 11 (depends on 8)

The method of claim 8 wherein the diabetes is type 1.

### Claim 12 (depends on 8)

The method of claim 8 wherein the diabetes is type 2.

### Claim 13 (depends on 7)

The method of claim 7 wherein the compound is selected from the following:

### Claim 14 (depends on 8)

The method of claim 8 wherein the compound is selected from the following:
